The transcriptional activity of MEF2C is impaired in PAECs from individuals with PAH due to increased nuclear localization of inhibitory class IIa HDACs HDAC4 and HDAC5 (58). The gene discussed is MEF2C; the disease is pulmonary arterial hypertension.